RedDress ActiGraft+ System Shows Positive Results for Complex Wound Care

January 20, 2023—RedDress Ltd. announced the publication of new data outlining the company’s ActiGraft+ wound care product for use on complex wounds. RedDress is a privately held Israel-based medical device company with a United States subsidiary, RedDress Inc., located in Ponte Vedra Beach, Florida.

The RedDress ActiGraft and ActiGraft+ are FDA-cleared wound care solutions that enable health care providers to produce—in real time—an in vitro blood clot from a patient’s whole blood. Once applied, the blood clot serves as a protective covering and supports wound healing processes that naturally occur in the patient’s body. ActiGraft and ActiGraft+ are intended for exuding cutaneous wounds, advised the company.

The findings from a consensus panel were published by Robert J. Snyder, DPM, et al in Wounds (2023;35:2-8).

According to RedDress, the consensus panel included a core group of nine clinicians from the United States and Germany with extensive experience in wound care and surgical wound care management. The panel developed a consensus of decision pathways and recommendations for topical autologous blood clot therapy (TABCT) for use in specific complex wound types.

The clinicians in the panel defined four recommendations focused on complex diabetic foot ulcers, pressure injuries, venous ulcers, and surgical wounds that had tunneling, exposed bone and/or tendon, and could not undergo sharp debridement.

The company reported the recommendation as follows:

• TABCT should be applied to wounds after adequate debridement in patients in which this can be performed. For patients who cannot undergo debridement, TABCT is still a viable treatment option because it maintains a moist wound environment that can aid in autolytic debridement.
• TABCT can be used as a physical barrier to prevent bacteria from the surrounding skin and the external environment from entering the wound bed.
• TABCT is a viable treatment option for patients with irregular wound beds or tunneling. The flowable solution is able to fill the entire wound bed allowing the application to send beneficial growth factors to the wound.
• TABCT can be used in full-thickness wounds with exposed tendon and/or bone to serve as a barrier to bacterial ingress and to assist in maintenance of a moist wound-healing environment to aid in conversion from a proinflammatory to an anti-inflammatory state of healing and pre¬vent desiccation and/or necrosis of exposed structures.

The panel concluded that ActiGraft+ is a viable option for these complex wounds because it can assist in autolytic debridement, achieve complete wound bed coverage, maintain a moist wound healing environment, and provide structural support necessary for wound healing to occur.

“Autologous therapies are considered the latest cutting-edge technology to be utilized in wound care,” commented Dr. Snyder in the company's press release. “These statements as well as previously published clinical data highlight that using autologous therapies on complex, hard-to-heal wounds is an effective and viable solution for the patient.”

In addition to the four consensus statements, the panel integrated ActiGraft+ into the DIME wound care management model, as outlined in a graph in Wound: Debridement; Infection/Inflammation; Moisture Management; and Edge.